”Axpaxli is the only other superiority wet amd drug in ph3 trials - I don’t know much about it but dr wyoff brushed it off as trials being run in an atypical way vs OPT trial which is based on a solid / gold standard trial design
here is more info: https://www.biospace.com/press-releases/ocular-therapeutix-shares-sol-r-enrollment-progress-and-next-steps-for-axpaxli-in-npdr
The company for this drug is similar size to OPT
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable